Mykofenolatmofetil Accord (Mycophenolate Mofetil)

Mycophenolate Mofetil is used to modulate immune responses in several clinical settings:

• Prevention of acute organ transplant rejection: reduces the incidence of graft rejection by suppressing T‑cell activity.
• Systemic lupus erythematosus: helps control disease activity and flares in patients with severe manifestations.
• Vasculitis: contributes to disease control by limiting immune‑mediated vascular inflammation.

• Mycophenolate Mofetil selectively and reversibly inhibits inosine monophosphate dehydrogenase (IMPDH), a key enzyme in the de novo synthesis of guanosine nucleotides. This inhibition lowers intracellular guanosine levels, which preferentially impairs proliferation of B and T lymphocytes that rely on this pathway, thereby dampening the adaptive immune response.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: loose stools, sometimes leading to dehydration.
• Vomiting: occasional emesis.
• Abdominal pain: crampy discomfort.
• Headache: transient mild headache.
• Mild infections: increased susceptibility to common colds.

Serious or Rare Side Effects

• Severe infections: opportunistic or life‑threatening infections.
• Bone marrow suppression: leukopenia, anemia, or thrombocytopenia.
• Hepatic toxicity: elevated liver enzymes or hepatitis.
• Malignancy risk: increased incidence of certain cancers with long‑term use.
• Progressive multifocal leukoencephalopathy (PML): rare demyelinating disease.
• Teratogenicity: fetal harm when exposure occurs during pregnancy.

Mycophenolate Mofetil requires careful monitoring and specific safety measures.

• Pregnancy: contraindicated (Category X); avoid use in women of childbearing potential unless effective contraception is used.
• Blood counts: monitor complete blood count regularly to detect leukopenia or anemia.
• Liver function: assess hepatic enzymes periodically, especially in patients with pre‑existing liver disease.
• Live vaccines: avoid administration while on therapy due to reduced immune competence.
• Drug interactions: review concomitant medications for potential additive immunosuppression.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Mycophenolate Mofetil can interact with several drug classes, affecting efficacy or safety.

Major Interactions (Avoid)

• Antimetabolites (e.g., azathioprine): additive bone‑marrow suppression.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce drug exposure.
• Live viral vaccines: increased risk of severe infection.

Moderate Interactions (Monitor Closely)

• Antacids containing magnesium or aluminum: may decrease absorption.
• ACE inhibitors or ARBs: potential for increased renal toxicity.
• Cholesterol‑lowering agents (e.g., statins): heightened risk of myopathy.
• Vaccines (non‑live): monitor immune response efficacy.